Resources

Products

Applications

About MGI

Resources

Products

Applications

About MGI

MGI Introduces Next-Generation Sequencing to Riga 3rd Gymnasium Students

10/19/23

Offline

Riga, Latvia

Share

MGI introduced the future of genomics to Riga 3rd Gymnasium students, offering hands-on experience with the cutting-edge DNBSEQ-T10 Next-Generation Sequencing technology to inspire and cultivate the next generation of scientists.
MGI introduced the future of genomics to Riga 3rd Gymnasium students, offering hands-on experience with the cutting-edge DNBSEQ-T10 Next-Generation Sequencing technology to inspire and cultivate the next generation of scientists.
MGI introduced the future of genomics to Riga 3rd Gymnasium students, offering hands-on experience with the cutting-edge DNBSEQ-T10 Next-Generation Sequencing technology to inspire and cultivate the next generation of scientists.

Students from Riga 3rd Gymnasium recently had the opportunity to engage with MGI Latvia's cutting-edge DNBSEQ-T10 Next-Generation Sequencing technology. The hands-on experience aimed to inspire these young minds and provide insights into the latest advancements in Life Sciences.

MGI Latvia's commitment to supporting education and nurturing young talents was evident in this initiative. By offering students exclusive access to MGI technologies, the facility not only makes advanced tools accessible but also contributes to fostering future innovators in the field.

During the guided tour and Life Sciences class, students gained valuable insights into the world of Next-Generation Sequencing, emphasizing its potential impact across various industries and research fields.

This initiative reflects MGI's dedication to advancing genomics and inspiring the next generation of scientists and researchers. As we celebrate this intersection of education and innovation, MGI looks forward to continuing its mission of making genomics accessible and inspiring future leaders in the Life Sciences.

Students from Riga 3rd Gymnasium recently had the opportunity to engage with MGI Latvia's cutting-edge DNBSEQ-T10 Next-Generation Sequencing technology. The hands-on experience aimed to inspire these young minds and provide insights into the latest advancements in Life Sciences.

MGI Latvia's commitment to supporting education and nurturing young talents was evident in this initiative. By offering students exclusive access to MGI technologies, the facility not only makes advanced tools accessible but also contributes to fostering future innovators in the field.

During the guided tour and Life Sciences class, students gained valuable insights into the world of Next-Generation Sequencing, emphasizing its potential impact across various industries and research fields.

This initiative reflects MGI's dedication to advancing genomics and inspiring the next generation of scientists and researchers. As we celebrate this intersection of education and innovation, MGI looks forward to continuing its mission of making genomics accessible and inspiring future leaders in the Life Sciences.

Students from Riga 3rd Gymnasium recently had the opportunity to engage with MGI Latvia's cutting-edge DNBSEQ-T10 Next-Generation Sequencing technology. The hands-on experience aimed to inspire these young minds and provide insights into the latest advancements in Life Sciences.

MGI Latvia's commitment to supporting education and nurturing young talents was evident in this initiative. By offering students exclusive access to MGI technologies, the facility not only makes advanced tools accessible but also contributes to fostering future innovators in the field.

During the guided tour and Life Sciences class, students gained valuable insights into the world of Next-Generation Sequencing, emphasizing its potential impact across various industries and research fields.

This initiative reflects MGI's dedication to advancing genomics and inspiring the next generation of scientists and researchers. As we celebrate this intersection of education and innovation, MGI looks forward to continuing its mission of making genomics accessible and inspiring future leaders in the Life Sciences.

Students from Riga 3rd Gymnasium recently had the opportunity to engage with MGI Latvia's cutting-edge DNBSEQ-T10 Next-Generation Sequencing technology. The hands-on experience aimed to inspire these young minds and provide insights into the latest advancements in Life Sciences.

MGI Latvia's commitment to supporting education and nurturing young talents was evident in this initiative. By offering students exclusive access to MGI technologies, the facility not only makes advanced tools accessible but also contributes to fostering future innovators in the field.

During the guided tour and Life Sciences class, students gained valuable insights into the world of Next-Generation Sequencing, emphasizing its potential impact across various industries and research fields.

This initiative reflects MGI's dedication to advancing genomics and inspiring the next generation of scientists and researchers. As we celebrate this intersection of education and innovation, MGI looks forward to continuing its mission of making genomics accessible and inspiring future leaders in the Life Sciences.

About MGI

MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.

MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.

The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.

For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.

About MGI

MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.

MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.

The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.

For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.

About MGI

MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.

MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.

The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.

For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.

About MGI

MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.

MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.

The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.

For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.

GENOMICS

LIFE SCIENCE INNOVATION

NGS

DNBSEQ

EDUCATION

Share this article :

Share

Sep 10, 2024

MGI Tech Unveils its SEQ ALL landscape at the Future of Omics Conference

Discover insights from the "Future of Omics" event, where leading experts discussed innovations in genomics, proteomics, and metabolomics. Explore key takeaways on advancing research and technology, shaping the future of personalized medicine and healthcare. Join us in celebrating the progress in omics!

Jun 1, 2024

MGI Tech Shares New Data on Core DNEBSEQ Technology and Showcases Latest Sequencing Innovations at ESHG 2024

MGI showcased its latest innovations at the ESHG 2024, highlighting the upgraded StandardMPS 2.0 sequencing chemistry and unveiling the new DNBelab C-TaiM 4 Single-Cell Droplet Generator. European researchers presented advancements in diagnostics, population health, and more.

Apr 27, 2024

MGI Showcases New DNBSEQ-E25 Sequencer & Partners with ABL Diagnostics at ESCMID Global 2024

MGI introduced its portable DNBSEQ-E25 sequencer at ESCMID Global 2024, designed for mobile and efficient genomic sequencing with applications in infectious diseases. Additionally, MGI announced a partnership with ABL Diagnostics to integrate DeepChek® assays into its platforms, broadening NGS solutions for microbiology labs.

Join our newsletter to stay up to date on features and releases.

I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.

*For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.

Join our newsletter to stay up to date on features and releases.

I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.

*For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.

Join our newsletter to stay up to date on features and releases.

I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.

*For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.

Join our newsletter to stay up to date on features and releases.

I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.

*For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.